IV-23 (Compound 20) is a potent Noxa mediated apoptosis inducer, and it is a promising anticancer agent with potential. IV-23 inhibits cell growths in vitro and in vivo, reduces colony formation, arrests cell cycle at M phase, and induces esophageal squamous cell carcinoma (ESCC)^[1].

IV-23 (Compound 20) shows a strong inhibition against the ESCCs in a concentration depend manner, the IC₅₀ values against the Kyse30 and Kyse450 cell lines were all less than 2 μM, presented in a dose-dependent manner. IV-23 triggeres caspases related apoptosis in ESCC cells^[1].
IV-23 induces G2/M phase arrest^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

392.24

C₁₈H₁₈BrNO₄

2326007-49-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fu DJ, et al. Discovery of indoline derivatives that inhibit esophageal squamous cell carcinoma growth by Noxa mediated apoptosis. Bioorg Chem. 2019 Aug 10;92:103190.